Prenatal screening tests devices Market

Growing maternal age is driving the market growth

Market CAGR for prenatal screening tests devices is being driven by the Growing Maternal Age. Prenatal testing gives you details about the health of your unborn child. It finds any issues, including as genetic flaws and congenital disorders that might have an impact on the health of fetuses. While some women require specialized screening procedures, doctors advise certain prenatal screenings. Testing is done on newborns to find anomalies that may lead to inborn genetic disorders or other health issues. During screening, genetic disorders such as homocystinuria, phenylketonuria, and Down syndrome can be identified in neonates.

Additionally, the tendency to put off having children raises the risk of chromosomal abnormalities and genetic illnesses in babies. Prenatal screening tests to identify such anomalies are becoming more and more necessary as more women want to become pregnant at older ages. Growth in the industry is stimulated by increased healthcare spending, particularly in developed and emerging nations where it leads to better access to screening tests and prenatal care.

However, due to high costs or inadequate healthcare infrastructure, access to advanced prenatal screening tests may be restricted in some areas or healthcare settings, which could have an impact on broad adoption.

A greater frequency of chromosomal abnormalities and genetic illnesses in babies is a result of the trend of postponing delivery. Prenatal screening tests are becoming more and more necessary to identify these anomalies as more women choose to become pregnant at older ages. Prenatal screening tests that don't involve risk are more frequently adopted because expectant parents are drawn to non-invasive, risk-free ways of keeping an eye on their unborn child's health. 

Prenatal screening tests are in high demand because early discovery of fetal anomalies enables better medical management and educates parents and healthcare providers in making decisions. For instance, the World Health Organization (WHO) estimates that congenital anomalies account for 6% of all births and are a major contributor to the  illness burden, particularly in low- and middle-income nations. Additionally, the Prenatal and Newborn Genetic Testing Market Size is positively impacted by the increase in demand for non-invasive prenatal screening. Thus, result in driving the prenatal screening tests devices market revenue.

The Global Prenatal Screening Tests Devices Market Industry is projected to experience substantial growth in the coming years. With a market value of 0.89 USD Billion in 2024, it is expected to reach 2.81 USD Billion by 2035, indicating a robust expansion trajectory. The compound annual growth rate (CAGR) of 10.97% from 2025 to 2035 reflects the increasing demand for prenatal screening solutions driven by various factors, including technological advancements, rising awareness, and government initiatives. This growth presents opportunities for stakeholders in the industry to innovate and expand their offerings, catering to the evolving needs of expectant mothers and healthcare providers.

The rise in global healthcare expenditure is positively impacting the Global Prenatal Screening Tests Devices Market Industry. As countries allocate more resources to healthcare, there is a corresponding increase in funding for prenatal care services. This trend is particularly pronounced in developed nations, where healthcare budgets are expanding to include advanced prenatal screening technologies. Increased investment in healthcare infrastructure and services enhances the availability and accessibility of prenatal screening tests, thereby driving market growth. The anticipated growth from 0.89 USD Billion in 2024 to 2.81 USD Billion by 2035 underscores the potential for continued expansion in this sector.

Government initiatives aimed at improving maternal health are significantly influencing the Global Prenatal Screening Tests Devices Market Industry. Various countries are implementing policies that promote access to prenatal care and screening services. Funding for research and development of new screening technologies is also on the rise, which further supports market growth. For instance, government programs that subsidize the cost of prenatal screenings make these services more accessible to a broader population. This increased accessibility is expected to drive market expansion, contributing to the projected growth from 0.89 USD Billion in 2024 to 2.81 USD Billion by 2035.

The increasing awareness regarding prenatal health among expectant mothers is a key driver for the Global Prenatal Screening Tests Devices Market Industry. Educational initiatives and healthcare campaigns have significantly contributed to this awareness, leading to a higher demand for prenatal screening tests. As more women understand the importance of early detection of genetic disorders and other complications, the market is expected to grow. In 2024, the market is valued at 0.89 USD Billion, reflecting this heightened awareness. This trend is likely to continue, as healthcare providers emphasize the necessity of prenatal screenings for better maternal and fetal health outcomes.

The rising incidence of genetic disorders among newborns is a critical factor propelling the Global Prenatal Screening Tests Devices Market Industry. As the prevalence of conditions such as Down syndrome and other chromosomal abnormalities increases, the demand for effective prenatal screening solutions grows correspondingly. This trend is particularly evident in regions with advanced healthcare systems, where early detection is prioritized. The market's growth is further supported by the increasing number of women opting for advanced maternal age pregnancies, which correlates with a higher risk of genetic disorders. Consequently, the market is poised for substantial growth as more families seek comprehensive prenatal screening options.

Technological innovations in prenatal screening devices are transforming the Global Prenatal Screening Tests Devices Market Industry. The introduction of non-invasive prenatal testing (NIPT) and advanced imaging techniques has enhanced the accuracy and reliability of screenings. These advancements not only improve diagnostic capabilities but also reduce the risks associated with invasive procedures. As a result, healthcare providers are increasingly adopting these technologies, which is reflected in the market's growth trajectory. The anticipated compound annual growth rate (CAGR) of 10.97% from 2025 to 2035 indicates a robust expansion driven by ongoing technological improvements.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American prenatal screening tests devices market area will dominate this market. Newborns in North America are more likely to have chromosomal abnormalities and genetic illnesses as a result of the tendency of women delaying childbirth. As a result, older pregnant mothers are calling for prenatal screening tests more frequently.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure2:  PRENATAL SCREENING TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe prenatal screening tests devices market has the second-largest portion of the market. Prenatal screening test uptake and general availability are supported by this infrastructure. Further, the German prenatal screening tests devices market held the largest proportion of the market, and the UK prenatal screening tests devices market was the European market with the quickest rate of growth.

The Asia-Pacific Prenatal screening tests devices Market has the quickest predicted compound annual growth rate (CAGR) between 2023 and 2032. Infrastructure improvements for healthcare, particularly in the region's fast developing economies. Moreover, China’s prenatal screening tests devices market had the biggest market share, and the Indian prenatal screening tests devices market was the Asia-Pacific region's fastest-growing market.

Leading market players are putting a lot of money on R&D to expand their product lines, which will drive the market for prenatal screening test devices to continue growing. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, prenatal screening tests devices industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  prenatal screening tests devices industry to help customers and expand the market segment. In recent years, the prenatal screening tests devices industry has provided some of the biggest benefits to medicine. Major players in the prenatal screening tests devices market, including Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc., and others, are engaging in research and development activities in an effort to boost market demand.

Illumina creates and sells integrated solutions for biological function and genetic variation analysis. Illumina recorded revenue growth of about 6% in 2019. The business put forth an acquisition proposal for Pacific Biosciences that same year for $8.00 per share, or about $1.2 billion. Illumina revealed in 2020 that it will pay $8 billion in cash and stock to purchase Grail. The goal of Illumina's iHope Genetic Health program, which was launched in 2021 in partnership with Genetic Alliance, is to give low- and middle-income populations affected by genetic disease access to whole genome sequencing.

BGI Genomics is a Chinese genomics company that offers genomic testing and research services to medical organizations, research institutes, businesses, and public agencies. The functional microbiome analyses were made possible by the publication of 1,520 reference genomes from farmed human gut bacteria by BGI Genomics in 2019. Using its in-house DNBSEQ TM technology platform, BGI has been offering a rapid whole genome sequencing (rWGS) service since 2019. This service is designed to expedite the processing of massive sequencing data. A BGI subsidiary, Forensic Genomics International, developed a nationwide genetic profile database that was compatible with WeChat in the same year.